tradingkey.logo

Cytek Biosciences Inc

CTKB
5.100USD
+0.030+0.59%
收盤 12/26, 16:00美東報價延遲15分鐘
652.11M總市值
虧損本益比TTM

Cytek Biosciences Inc

5.100
+0.030+0.59%

關於 Cytek Biosciences Inc 公司

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.

Cytek Biosciences Inc簡介

公司代碼CTKB
公司名稱Cytek Biosciences Inc
上市日期Jul 23, 2021
CEOJiang (Wenbin)
員工數量648
證券類型Ordinary Share
年結日Jul 23
公司地址47215 Lakeview Boulevard
城市FREMONT
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94538
電話18779229835
網址https://cytekbio.com
公司代碼CTKB
上市日期Jul 23, 2021
CEOJiang (Wenbin)

Cytek Biosciences Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Mr. Michael Holder
Mr. Michael Holder
Independent Director
Independent Director
12.36K
+21.43%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.07M
+0.26%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.36M
+0.79%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
115.64K
+16.63%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%
地區USD
名稱
營收
佔比
United States
23.89M
52.40%
EMEA
12.31M
26.99%
APAC
7.87M
17.25%
Other
1.53M
3.36%
業務
地區
業務USD
名稱
營收
佔比
Biotechnology, pharmaceutical, distributor and CRO
23.85M
52.30%
Academia and government
21.75M
47.70%

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
其他
67.30%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
11.89%
Topline Capital Management, LLC
5.43%
The Vanguard Group, Inc.
5.42%
HHLR Advisors, Ltd.
5.21%
Yan (Ming)
4.75%
其他
67.30%
股東類型
持股股東
佔比
Investment Advisor
28.05%
Investment Advisor/Hedge Fund
22.30%
Hedge Fund
9.95%
Individual Investor
9.31%
Research Firm
1.43%
Pension Fund
1.21%
Bank and Trust
0.17%
Family Office
0.12%
Venture Capital
0.06%
其他
27.39%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
319
80.93M
70.83%
-2.20K
2025Q3
325
80.93M
70.98%
+589.69K
2025Q2
322
80.49M
71.67%
+1.88M
2025Q1
319
78.68M
72.45%
-13.77M
2024Q4
315
78.50M
69.87%
+2.46M
2024Q3
291
75.89M
70.06%
-1.14M
2024Q2
277
76.97M
68.86%
-4.44M
2024Q1
273
87.08M
76.11%
-12.82M
2023Q4
268
85.37M
77.21%
+1.48M
2023Q3
258
83.84M
73.24%
+597.32K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
15.38M
12.09%
-1.12M
-6.80%
Jun 30, 2025
Topline Capital Management, LLC
5.23M
4.11%
+3.76M
+255.68%
Jun 30, 2025
The Vanguard Group, Inc.
7.74M
6.08%
-1.86M
-19.35%
Jun 30, 2025
HHLR Advisors, Ltd.
6.66M
5.23%
--
--
Jun 30, 2025
Yan (Ming)
6.06M
4.76%
+15.29K
+0.25%
Aug 18, 2025
Jiang (Wenbin)
5.31M
4.18%
+52.68K
+1.00%
Aug 18, 2025
Brown Capital Management, LLC
7.11M
5.59%
-353.97K
-4.74%
Jun 30, 2025
State Street Investment Management (US)
4.17M
3.28%
-208.41K
-4.76%
Jun 30, 2025
Millennium Management LLC
924.77K
0.73%
+429.33K
+86.66%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.45M
2.72%
+601.00K
+21.06%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco S&P SmallCap Health Care ETF
0.26%
Royce Quant Small-Cap Quality Value ETF
0.22%
iShares S&P Small-Cap 600 Value ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
State Street SPDR S&P 600 Small Cap Value ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Principal U.S. Small-Cap ETF
0.05%
WisdomTree US SmallCap Fund
0.04%
查看更多
Invesco S&P SmallCap Health Care ETF
佔比0.26%
Royce Quant Small-Cap Quality Value ETF
佔比0.22%
iShares S&P Small-Cap 600 Value ETF
佔比0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.07%
State Street SPDR S&P 600 Small Cap Value ETF
佔比0.06%
Avantis US Small Cap Equity ETF
佔比0.05%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
佔比0.05%
Fidelity Enhanced Small Cap ETF
佔比0.05%
Principal U.S. Small-Cap ETF
佔比0.05%
WisdomTree US SmallCap Fund
佔比0.04%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Cytek Biosciences Inc的前五大股東是誰?

Cytek Biosciences Inc的前五大股東如下:
BlackRock Institutional Trust Company, N.A.
持有股份:15.38M
佔總股份比例:12.09%。
Topline Capital Management, LLC
持有股份:5.23M
佔總股份比例:4.11%。
The Vanguard Group, Inc.
持有股份:7.74M
佔總股份比例:6.08%。
HHLR Advisors, Ltd.
持有股份:6.66M
佔總股份比例:5.23%。
Yan (Ming)
持有股份:6.06M
佔總股份比例:4.76%。

Cytek Biosciences Inc的前三大股東類型是什麼?

Cytek Biosciences Inc 的前三大股東類型分別是:
BlackRock Institutional Trust Company, N.A.
Topline Capital Management, LLC
The Vanguard Group, Inc.

有多少機構持有Cytek Biosciences Inc(CTKB)的股份?

截至2025Q4,共有319家機構持有Cytek Biosciences Inc的股份,合計持有的股份價值約為80.93M,占公司總股份的70.83% 。與2025Q3相比,機構持股有所增加,增幅為-0.14%。

哪個業務部門對Cytek Biosciences Inc的收入貢獻最大?

在FY2025Q2,Biotechnology, pharmaceutical, distributor and CRO業務部門對Cytek Biosciences Inc的收入貢獻最大,創收23.85M,占總收入的52.30% 。
KeyAI